Price$2.19-0.13 (-5.59%)
01:30 PM07:45 PM
News · 26 weeks48+200%
2026-04-192026-10-11
Mix1890d
- Insider8(44%)
- SEC Filings4(22%)
- Other3(17%)
- Earnings2(11%)
- Offering1(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Altimmune Inc.4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Altimmune Inc.4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer Menziuso Richard Thomas4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 3 filed by new insider Menziuso Richard Thomas3 - Altimmune, Inc. (0001326190) (Issuer)
- SECAltimmune Inc. filed SEC Form 8-K: Leadership Update8-K - Altimmune, Inc. (0001326190) (Filer)
- PRAltimmune to Participate in Stifel Cardiometabolic ForumGAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targetin
- INSIDERChief Commercial Officer Richardson Linda M covered exercise/tax liability with 6,826 shares and converted options into 24,000 shares (SEC Form 4)4 - Altimmune, Inc. (0001326190) (Issuer)
- PRAltimmune to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy target
- INSIDERPresident and CEO Durso Jerome Benedict bought $44,250 worth of shares (15,000 units at $2.95), increasing direct ownership by 32% to 62,500 units (SEC Form 4)4 - Altimmune, Inc. (0001326190) (Issuer)
- SECSEC Form 10-Q filed by Altimmune Inc.10-Q - Altimmune, Inc. (0001326190) (Filer)
- SECAltimmune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Altimmune, Inc. (0001326190) (Filer)
- PRAltimmune Announces Second Quarter 2026 Financial Results and Business UpdateInitiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We have achieved several important milestones as we continue to successfully execute our strategy, i
- PRAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website sho
- INSIDERChief Scientific Officer Roberts M Scot was granted 875 shares, increasing direct ownership by 0.78% to 113,699 units (SEC Form 4)4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERChief Financial Officer Weaver Gregory L was granted 1,753 shares, increasing direct ownership by 5% to 39,831 units (SEC Form 4)4 - Altimmune, Inc. (0001326190) (Issuer)
- PRAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHGlobal registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes Initiation marks advancement of Altimmune's lead program into late-stage development following positive IMPACT Phase 2b data GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Pemvidutide is an investigational balanced glucagon/GLP-1 dual
- SECAltimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Altimmune, Inc. (0001326190) (Filer)
- PRAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use DisorderPemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM P
- ANALYSTLeerink Partners initiated coverage on Altimmune with a new price targetLeerink Partners initiated coverage of Altimmune with a rating of Outperform and set a new price target of $10.00
- SECAltimmune Inc. filed SEC Form 8-K: Other Events8-K - Altimmune, Inc. (0001326190) (Filer)
- PRPemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026"Best of EASL" oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple cardiometabo
- PRAltimmune to Participate in Upcoming Investor ConferencesGAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical co
- PRNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tes
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)
- SECSEC Form S-8 filed by Altimmune Inc.S-8 - Altimmune, Inc. (0001326190) (Filer)
ALT FAQ
6 questionsWhat does Altimmune Inc. do?
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant...Where does ALT stock trade?
Altimmune Inc. (ALT) is listed on NASDAQ.What sector and industry is ALT in?
Altimmune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ALT?
Altimmune Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $1000.00 price target on 2026-06-22.What companies are similar to ALT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ALT side-by-side with any of them on Quantisnow.How can I track ALT on Quantisnow?
Quantisnow aggregates Altimmune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALT to receive live email and push alerts on every new disclosure.